Skip to main content
Premium Trial:

Request an Annual Quote

Scriptgen Subscribes to Genome Therapeutics' Microbial Database

Premium

WALTHAM, Mass.--Genome Therapeutics and Scriptgen Pharmaceuticals have entered into a licensing agreement that will provide Scriptgen with nonexclusive access to Genome Therapeutics' proprietary microbial sequence database, PathoGenome. The database of sequence information on medically relevant microbial organisms and fungi will allow researchers at Scriptgen to identify gene targets, which it says will aid in the discovery of novel therapeutics for treating infectious diseases and drug-resistant organisms.

Scriptgen will pay annual subscription fees and milestone payments, as well as royalties on products developed as a result of the use of the database. Genome Thera peutics claimed that Patho Genome is the most comprehensive commercial source of microbial genomic information available.

The nonexclusive database is designed for use at the client site utilizing proprietary bioinformatics software developed at Genome Therapeutics. Bayer, Bristol-Myers Squibb and Schering-Plough also subscribe to PathoGenome.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.